Home

Trevi Therapeutics, Inc. - Common Stock (TRVI)

3.9400
+0.0400 (1.03%)

Trevi Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for chronic conditions with high unmet medical needs

The company's primary focus is on utilizing its proprietary formulation technology to create treatments for neurological and chronic pain disorders, including pruritus associated with specific dermatological conditions. Through advanced research and clinical trials, Trevi aims to bring new, effective solutions to patients suffering from debilitating symptoms, thereby improving their quality of life.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close3.900
Open3.900
Bid3.840
Ask4.000
Day's Range3.810 - 3.970
52 Week Range1.350 - 4.680
Volume383,085
Market Cap236.67M
PE Ratio (TTM)-8.955
EPS (TTM)-0.4
Dividend & YieldN/A (N/A)
1 Month Average Volume503,396

News & Press Releases

12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · December 12, 2024
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higherbenzinga.com
Via Benzinga · December 12, 2024
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlookmarkets/com
Via Benzinga · December 12, 2024
Nasdaq Down 50 Points; US Initial Jobless Claims Risebenzinga.com
Via Benzinga · December 12, 2024
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?benzinga.com
Trevi Therapeutics' CORAL trial progresses unchanged after a positive SSRE review, with topline results for chronic cough in IPF expected by mid-2025.
Via Benzinga · December 12, 2024
Trevi Therapeutics: Q4 Earnings Insightsbenzinga.com
Via Benzinga · March 20, 2024
Earnings Outlook For Trevi Therapeuticsbenzinga.com
Via Benzinga · March 19, 2024
Trevi Therapeutics's Earnings: A Previewbenzinga.com
Via Benzinga · November 8, 2023
Recap: Trevi Therapeutics Q1 Earningsbenzinga.com
Via Benzinga · May 11, 2023
Why Trevi Therapeutics Could Be a Triple-Bagger Biotech Stock
Wall Street analysts see big potential upside for small-cap biopharma firm Trevi Therapeutics. So, what does the firm do and how does it stand out?
Via MarketBeat · September 6, 2024
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024investorplace.com
TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · June 6, 2024
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024investorplace.com
TRVI stock results show that Trevi Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 7, 2024
TRVI Stock Earnings: Trevi Therapeutics Beats EPS for Q4 2023investorplace.com
TRVI stock results show that Trevi Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 20, 2024
Earnings Preview: Trevi Therapeuticsbenzinga.com
Via Benzinga · May 10, 2023
Earnings Scheduled For March 20, 2024benzinga.com
Companies Reporting Before The Bell • UP Fintech Holding (NASDAQTIGR) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
Via Benzinga · March 20, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 1, 2023
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · April 18, 2023
Earnings Scheduled For November 9, 2023benzinga.com
Companies Reporting Before The Bell • Indivior (NASDAQINDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.
Via Benzinga · November 9, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · April 18, 2023
Earnings Scheduled For August 10, 2023benzinga.com
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQIDBA) is estimated to report quarterly loss at $0.39 per share on revenue of $1.60 million.
Via Benzinga · August 10, 2023
Earnings Scheduled For May 11, 2023benzinga.com
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSETAK) is likely to report earnings for its fourth quarter. • Exela Technologies NASDAQ:XELANASDAQXELA)
Via Benzinga · May 11, 2023
Earnings Scheduled For March 16, 2023benzinga.com
Companies Reporting Before The Bell • KVH Industries (NASDAQKVHI) is projected to report quarterly earnings at $0.03 per share on revenue of $34.29 million.
Via Benzinga · March 16, 2023
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Sessionbenzinga.com
Gainers Glory Star New Media Group Holdings Limited (NASDAQGSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional investors at $2.48 per share.
Via Benzinga · April 18, 2023
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2023benzinga.com
Via Benzinga · April 12, 2023